Sotheby’s has announced that it is to be acquired by billionaire telecom magnate and art collector Patrick Drahi in a surprise $3.7 billion deal
Sotheby’s has announced that it is to be acquired by billionaire telecom magnate and art collectorDrahi’s wholly-owned entity BidFair USA has paid $57.00 in cash per share of Sotheby’s common stock. The offer price represents a premium of 61% to Sotheby's closing price on June 14, 2019, and a 56.3% premium to the company’s 30-trading-day volume-weighted average share price.
Patrick Drahi said he was “honored” to work with Sotheby’s on the deal. He said, “Sotheby’s is one of the most elegant and aspirational brands in the world,” thanking the Sotheby’s board for its support. Henri Matisse’s “Vase d'anémones” Est: £4,000,000-6,000,000, will be offered at the Impressionist & Modern Art Evening Sale on June 19 at Sotheby's London.On the future of the world-famous auction house, he adds, “This acquisition will provide Sotheby’s with the opportunity to accelerate the successful program of growth initiatives of the past several years in a more flexible private environment.
Raymond Stochel, Senior Equity Research Analyst at Consumer Edge says that for Sotheby's, Mr Drahi is a good fit for the future. He said, “We see this as syncing with the 'trophy buyer' thesis ... the transaction is expected to be paid in cash - not subject to availability of financing - and he is an art collector.”Patrick Drahi is a French-Israeli businessman with French, Portuguese and Israeli citizenship.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Billionaire Patrick Drahi agrees to buy Sotheby's in $3.7 billion dealPatrick Drahi, the billionaire behind telecoms and media group Altice, agreed on...
Read more »
Billionaire Patrick Drahi snaps up Sotheby's in $3.7 billion dealPatrick Drahi, the billionaire behind telecoms and media group Altice, agreed on...
Read more »
Pfizer to Buy Cancer Drug Maker Array BioPharma for $10.64 BillionPfizer agreed to buy Array BioPharma for $10.64 billion in cash, as the pharmaceutical company looks to expand its pipeline of cancer therapies.
Read more »
Pfizer to buy cancer drug developer Array Biopharma for $10.64 billionPfizer said on Monday it had agreed to acquire Array Biopharma for $10.64 billion, which will grant it access to its cancer drugs.
Read more »
Puerto Rico's oversight board strikes $35 billion restructuring deal with commonwealth's bondholdersThe agreement, which is on the framework for the plan of adjustment, provide for more than a 60% average haircut for all $35 billion, a 36% haircut on pre-2012 general obligation or 'GO' bonds, and a 27% haircut on public authority bonds that carry a constitutional guarantee on payment.
Read more »
Pfizer bolsters cancer portfolio with $10.64 billion deal for ArrayPfizer Inc on Monday struck a deal to buy Array Biopharma Inc for $10.64 billion...
Read more »